Leavenworth’s contributions bridge laboratory research with clinical applications, paving the way for innovative cancer ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...

targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information ...

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from ...

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.

Representatives from four leading companies highlight emerging basic and clinical research that drives renewed optimism.

Multiparametric magnetic resonance imaging (MRI)-based machine learning techniques have the potential to identify B-cell lymphoma-6 (BCL-6) overexpression in patients with primary central nervous ...